August 3rd, 2010
Three Questions about Ticagrelor: Part 1 — Sanjay Kaul
Sanjay Kaul, MD
PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US showed no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses of aspirin used […]
July 28th, 2010
FDA Cardiorenal Advisory Panel Recommends Ticagrelor Approval
Larry Husten, PHD
The Cardiovascular and Renal Drugs Advisory Committee recommended today that ticagrelor (Brilinta, AstraZeneca) be approved for the treatment of STEMI and NSTEMI patients intended to be managed both invasively and medically. The committee spent most of the day trying to sort through the confusing finding in the pivotal PLATO trial that U.S. patients, unlike patients […]
NEJM Journal Watch — Recent Cardiology Articles- Stroke Risk in Patients with Atrial Fibrillation and Concomitant Cancer
- Can a Factor XI Inhibitor Provide the Anticoagulation Effectiveness of DOACs for AF While Improving Safety?
- MEK Inhibition in Children with RASopathy-Associated Hypertrophic Cardiomyopathy
- Do Older STEMI Patients with Cardiogenic Shock Benefit from Microaxial Flow Pump Use?
- NEJM Journal Watch Cardiology Top Stories of 2024